MINT-IMATINIB TABLET

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

IMATINIB (IMATINIB MESYLATE)

Dostupné s:

MINT PHARMACEUTICALS INC

ATC kód:

L01EA01

INN (Mezinárodní Name):

IMATINIB

Dávkování:

400MG

Léková forma:

TABLET

Složení:

IMATINIB (IMATINIB MESYLATE) 400MG

Podání:

ORAL

Jednotky v balení:

15G/50G

Druh předpisu:

Prescription

Terapeutické oblasti:

ANTINEOPLASTIC AGENTS

Přehled produktů:

Active ingredient group (AIG) number: 0145503003; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2019-09-18

Charakteristika produktu

_MINT-IMATINIB(Imatinib Mesylate Tablets) _
_Page 1 of 74_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MINT-IMATINIB
Imatinib Mesylate Tablets
Tablets, 100 mg and 400 mg imatinib (as imatinib mesylate), Oral
Protein Kinase Inhibitor
ATC Code: L01EA01
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Initial Authorization:
SEP 18, 2019
Date of Revision:
NOV 14, 2023
Submission Control Number:
277157
_MINT-IMATINIB(Imatinib Mesylate Tablets) _
_Page 2 of 74_
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions, Musculoskeletal
11/2022
1 Indications
11/2023
4 Dosage and Administration
11/2023
7 Warnings and Precautions, General
11/2023
7 Warnings and Precautions, Hepatic/Biliary/Pancreatic
11/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................4
1.2
Geriatrics
..............................................................................................................................4
2
CONTRAINDICATIONS
.............................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................................
5
4
DOSAGE AND ADMINISTRATION
................................................................................